Trastuzumab pamirtecan, being developed under a 2023 partnership between BioNTech and DualityBio, elicited a 44.1% overall ...

Trastuzumab pamirtecan, a HER2-targeted antibody-drug conjugate, achieved ‘exceptional’ antitumor responses in patients with recurrent endometrial cancer, especially those with HER2 IHC 3+ tumors.

The Phase II cohort analysis included 145 patients whose conditions had progressed following initial chemotherapy.

Trastuzumab pamirtecan, an investigational HER2-targeted antibody-drug conjugate, met the primary efficacy endpoint in a Phase 2 cohort of ...

BioNTech will wind up its vaccine manufacturing plant in Singapore by February 2027 after a strategic review. Read more at straitstimes.com. Read more at straitstimes.com.

BioNTech has a rich pipeline that could help jolt the stock as it makes clinical progress. Intellia Therapeutics faces ...

The German biotechnology company currently employs 85 people at its manufacturing plant in Tuas.

By Bhanvi Satija LONDON, April 1 (Reuters) - Vaccine makers Pfizer and BioNTech halted a large U.S. trial of their updated COVID-19 vaccine in healthy adults aged 50 to 64, saying enrollment in the ...

The fight for two tumor types is poised to intensify, with BioNTech lining up a challenge to AstraZeneca, while SynOx Therapeutics is planning to enter a market served by companie ...

While BioNTech's substantial cash reserve of 17.2 billion euros provides a near-term buffer, the company faces a costly transition. Research and development expenses are projected to climb to as much ...

German biotech BioNTech today announced positive results from the primary analysis of a Phase II cohort evaluating German ...

On the heels of a comprehensive review, BioNTech has decided “to close its planned Singapore site by the end of February 2027 ...